4.5 Article

PharmGKB and the international warfarin pharmacogenetlics consortium: The changing role for pharmacogenomic databases and single-drug pharmacogenetics

期刊

HUMAN MUTATION
卷 29, 期 4, 页码 456-460

出版社

WILEY-LISS
DOI: 10.1002/humu.20731

关键词

warfarin; CYP2C9; VKORC1; pharmacogenetics; pharmacogenomics; PharmGKB; SNPs; IWPC

资金

  1. NIGMS NIH HHS [UO1GM61374] Funding Source: Medline

向作者/读者索取更多资源

PharmGKB, the pharmacogenetics and pharmacogenomics knowledge base (www.pharmgkb.org) is a publicly available online resource dedicated to the dissemination of how genetic variation leads to variation in drug responses. The goals of PharmGKB are to describe relationships between genes, drugs, and diseases, and to generate knowledge to catalyze pharmacogenetic and pharmacogenomic research. PharmGKB delivers knowledge in the form of curated literature annotations, drug pathway diagrams, and very important pharmacogene (VIP) summaries. Recently, PharmGKB has embraced a new role-broker of pharmacogenomic data for data sharing consortia. In particular, we have helped create the International Warfarin Pharmacogenetics Consortium (IWPC), which is devoted to pooling genotype and phenotype data relevant to the anticoagulant warfarin. PharmGKI3 has embraced the challenge of continuing to maintain its original mission while taking an active role in the formation of pharmacogenetic consortia.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据